SAGE Therapeutics (SAGE) Misses Q2 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Sage Therapeutics (SAGE) PT Raised to $95 at Needham & Company
August 4, 2017 7:27 AM EDTNeedham & Company raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $95.00 (from $82.00) while maintaining a Buy rating.
Analyst Danielle Brill commented, "Sage plans to report data from seven trials by YE17. Expected first in 3Q are results from the Brexanolone Phase 3 SRSE trial which... More
